CO6531416A2 - Vacunas y diagnóstico para torque teno virus porcino - Google Patents

Vacunas y diagnóstico para torque teno virus porcino

Info

Publication number
CO6531416A2
CO6531416A2 CO12047889A CO12047889A CO6531416A2 CO 6531416 A2 CO6531416 A2 CO 6531416A2 CO 12047889 A CO12047889 A CO 12047889A CO 12047889 A CO12047889 A CO 12047889A CO 6531416 A2 CO6531416 A2 CO 6531416A2
Authority
CO
Colombia
Prior art keywords
pttv
present
provides
infection
specific
Prior art date
Application number
CO12047889A
Other languages
English (en)
Inventor
Xiang-Jin Meng
Yaowei Huang
Original Assignee
Virginia Tech Intelectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intelectual Properties Inc filed Critical Virginia Tech Intelectual Properties Inc
Publication of CO6531416A2 publication Critical patent/CO6531416A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invención proporciona cuatro preparaciones purificadas que contienen una molécula de ácido polinucleico que codifica los genotipos del virus Torque teno porcino (PTTV) o subtipos PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, y PTTV2c-VA. La presente invención también proporciona clones de ADN infecciosos, plásmido biológicamente funcional o vector vírico que contiene la molécula de genoma de ácido nucleico infeccioso de los mismos. La presente invención proporciona además vacunas víricas exterminadas o subunidad de cápsida recombinantes purificadas y expresadas por vector, atenuadas, vivas para protección contra infección PTTV. La presente invención adicionalmente proporciona vacunas de subunidad que comprenden productos del gen específico PTTV, especialmente producto del gen de cápsida ORF1 para protección contra infección PTTV. Además, la presente invención proporciona métodos para diagnosticar infección PTTV por medio de reacción en cadena de polimerasa (PCR) usando cebador específico para genotipos PTTV1, PTTV2, y PTTV1 individual. Finalmente, la presente invención proporciona métodos para diagnosticarinfección PTTV por medio de métodos inmunológicos, por ejemplo, ensayo inmunoabsorbente ligado a la enzima (ELISA) y Western blot usando antígenos específicos de PTTV para detectar anticuerpos específicos PTTV de suero.
CO12047889A 2009-08-21 2012-03-21 Vacunas y diagnóstico para torque teno virus porcino CO6531416A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23583309P 2009-08-21 2009-08-21
US31651910P 2010-03-23 2010-03-23
US12/861,378 US9228242B2 (en) 2009-08-21 2010-08-23 Porcine torque teno virus vaccines and diagnosis

Publications (1)

Publication Number Publication Date
CO6531416A2 true CO6531416A2 (es) 2012-09-28

Family

ID=43605547

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12047889A CO6531416A2 (es) 2009-08-21 2012-03-21 Vacunas y diagnóstico para torque teno virus porcino

Country Status (19)

Country Link
US (2) US9228242B2 (es)
EP (2) EP2851428B1 (es)
JP (3) JP6002036B2 (es)
KR (3) KR101640062B1 (es)
CN (2) CN102712930B (es)
AU (1) AU2010292848B2 (es)
BR (1) BR112012003844B1 (es)
CA (1) CA2771771C (es)
CL (4) CL2012000452A1 (es)
CO (1) CO6531416A2 (es)
ES (1) ES2767781T3 (es)
HK (1) HK1249111A1 (es)
IN (1) IN2012DN02305A (es)
MX (1) MX344015B (es)
PL (1) PL2851428T3 (es)
RU (1) RU2553223C2 (es)
SG (1) SG178512A1 (es)
WO (1) WO2011031438A2 (es)
ZA (1) ZA201201949B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012003844B1 (pt) 2009-08-21 2021-05-04 Virginia Tech Intellectual Properties, Inc. proteína de capsídeo recombinante e vacina
EP2530170A1 (en) 2011-05-31 2012-12-05 Intervet International BV Torque Teno virus diagnostics
CN102590503B (zh) * 2012-01-20 2015-02-25 四川农业大学 一种猪细环病毒ⅱ型抗体间接阻断elisa检测试剂盒
CN103376317B (zh) * 2012-04-12 2015-11-18 徐超 不同疫苗适用性与经济性的现场判定方法
EP2653562A1 (en) 2012-04-20 2013-10-23 Institut Pasteur Anellovirus genome quantification as a biomarker of immune suppression
CN103014056B (zh) * 2012-11-23 2014-12-10 广东海大畜牧兽医研究院有限公司 一种猪Ⅱ型细环病毒TTSuV2-ORF1截短蛋白的酵母表达及应用
CN102998453B (zh) * 2012-11-23 2014-10-08 广东海大畜牧兽医研究院有限公司 一种猪Ⅰ型细环病毒TTSuV1抗体间接ELISA诊断试剂盒及其制备方法
CN103235121B (zh) * 2013-03-18 2015-08-05 江苏省农业科学院 一种检测猪输血传播病毒2型抗体的间接elisa试剂盒
RU2771533C2 (ru) * 2015-10-16 2022-05-05 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
CN107604098A (zh) * 2017-11-03 2018-01-19 福建省农业科学院畜牧兽医研究所 用于检测鸽TTV的EvaGreen实时荧光定量PCR引物及试剂盒
CN109061161B (zh) * 2018-11-14 2019-02-15 湖南省植物保护研究所 用于检测辣椒脉黄病毒的检测试剂盒及其应用
MX2022015802A (es) * 2020-06-12 2023-03-28 Flagship Pioneering Innovations V Inc Construcciones de anellovirus en tandem.
CA3206361A1 (en) * 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1061377C (zh) * 1996-12-13 2001-01-31 中国预防医学科学院病毒学研究所 能用于包装重组腺病毒伴随病毒的单疱病毒载体及其用途
CN1704119A (zh) * 2004-05-28 2005-12-07 上海佳牧生物制品有限公司 猪细小病毒病油乳剂灭活疫苗
EP2076284A4 (en) * 2006-10-05 2010-03-31 Cerebus Biolog Inc METHODS OF TREATING, PREVENTING AND DIAGNOSING TTV INFECTION IN PORK
KR101320192B1 (ko) * 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
BR112012003844B1 (pt) 2009-08-21 2021-05-04 Virginia Tech Intellectual Properties, Inc. proteína de capsídeo recombinante e vacina

Also Published As

Publication number Publication date
KR20140127903A (ko) 2014-11-04
AU2010292848A1 (en) 2012-04-12
US20110045019A1 (en) 2011-02-24
CA2771771C (en) 2018-09-11
PL2851428T3 (pl) 2019-12-31
CL2012000452A1 (es) 2013-07-05
JP2013502229A (ja) 2013-01-24
AU2010292848B2 (en) 2014-11-27
KR101721090B1 (ko) 2017-03-29
CN107522775A (zh) 2017-12-29
HK1249111A1 (zh) 2018-10-26
SG178512A1 (en) 2012-03-29
CA2771771A1 (en) 2011-03-17
WO2011031438A9 (en) 2011-08-18
RU2012110303A (ru) 2013-09-27
JP2017171663A (ja) 2017-09-28
KR20140110101A (ko) 2014-09-16
WO2011031438A2 (en) 2011-03-17
BR112012003844B1 (pt) 2021-05-04
WO2011031438A3 (en) 2011-06-30
IN2012DN02305A (es) 2015-08-21
JP6002036B2 (ja) 2016-10-05
ES2767781T3 (es) 2020-06-18
EP2851428A3 (en) 2015-04-29
MX2012002273A (es) 2012-09-07
MX344015B (es) 2016-12-02
EP2851428A2 (en) 2015-03-25
US20160216263A1 (en) 2016-07-28
EP2851428B1 (en) 2019-04-10
EP2467484A4 (en) 2013-06-12
ZA201201949B (en) 2013-05-29
RU2553223C2 (ru) 2015-06-10
JP6126176B2 (ja) 2017-05-10
CN102712930B (zh) 2017-06-13
EP2467484A2 (en) 2012-06-27
JP2015221819A (ja) 2015-12-10
BR112012003844A2 (pt) 2016-11-16
CL2014003561A1 (es) 2015-04-24
CN102712930A (zh) 2012-10-03
CL2014003563A1 (es) 2015-04-17
KR101640062B1 (ko) 2016-07-18
US9228242B2 (en) 2016-01-05
US9897605B2 (en) 2018-02-20
KR20120063489A (ko) 2012-06-15
CL2014003562A1 (es) 2015-04-24

Similar Documents

Publication Publication Date Title
CO6531416A2 (es) Vacunas y diagnóstico para torque teno virus porcino
Peacock et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry
Venereo-Sanchez et al. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate
Petsch et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Kim et al. Original antigenic sin responses to influenza viruses
Singh et al. Neutralizing antibodies protect against oral transmission of lymphocryptovirus
Nakauchi et al. Evaluation of reverse transcription loop‐mediated isothermal amplification assays for rapid diagnosis of pandemic influenza A/H1N1 2009 virus
WO2008115199A3 (en) Chimeric virus vaccines
Zhang et al. Glycoprotein E2 of classical swine fever virus expressed by baculovirus induces the protective immune responses in rabbits
Li et al. Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector
Alexander et al. Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C
RU2017125526A (ru) Пестивирус
Gong et al. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate
EP3430147B1 (en) Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer
Sistigu et al. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells
Cook et al. Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
Cheng et al. Enhancing expression of the classical swine fever virus glycoprotein E2 in yeast and its application to a blocking ELISA
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
Lee et al. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza
Wong et al. Designing efficacious vesicular stomatitis virus-vectored vaccines against Ebola virus
US20220323570A1 (en) Highly networked immunogen composition
Wahba et al. Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model
Cook et al. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies
Ferrantelli et al. A new concept on anti-SARS-CoV-2 vaccines: strong CD8+ T-cell immune response in both spleen and lung induced in mice by endogenously engineered extracellular vesicles